Kornimate/medical-research-clean huggingface dataset:
epidemiologic registry pethema lma 2015

Conditions: AML

Summary: epidemiologic and retrospective multicenter registry of all patients diagnosed with de novo or secondary acute myeloid leukemia (aml) in the pethema group institutions. this study is a non-interventional research regarding diagnosis and therapeutic approach

to perform this registry, every patient diagnosed with aml in the participant institutions, regardless type of aml and treatment administered, must be reported. it will be required to registry the main characteristics of the patients and aml at diagnosis, as cytomorphologic, immunophenotypic, and cytogenetic results, according to the habitual practice of the centers. the treatment which has been administered by every center of the pethema group, even when it is considered as supportive care, and evolution of the disease will also be reported (relapse o death). pethema group will input all the reported information in data bases

Eligibility criteria:
inclusion criteria: * patients diagnosed with acute myeloid leukemia exclusion criteria: * no exclusion criteria
177lu-p17-087/177lu-p17-088 in patients with metastatic castration-resistant prostate cancer

Conditions: Metastatic Castration-resistant Prostate Cancer

Summary: this is a pilot study to assess the safety and measure image-based absorbed dose of 177lu-p17-087/177lu-p17-088 in patients with metastatic castration-resistant prostate cancer (mcrpc) who will undergo radioliagnd therapy using 177lu-p17-087/177lu-p17-088. all patients underwent whole-body 68ga-psma pet/ct for selection and accepted intravenous injection with single dose 1.1 gbq (30 mci) of 177lu-p17-087/177lu-p17-088 within one week, then monitored at 1.5 hours, 4 hours, 24 hours, 48 hours, 72 hours, 120 hours and 168 hours after 177lu-p17-087/177lu-p17-088 administration with serial whole body planar and spect/ct imaging.

prostate cancer is the most frequent malignant tumor in men worldwide. prostate-specific membrane antigen (psma), is a surface molecule specifically expressed by prostate tumors which was shown to be a valid target for radiotherapy. 177lu-psma-617, a urea-based compound, provide an effective target for the treatment of metastatic castration-resistant prostate cancer. however, a major problem in the therapeutic use of 177lu-psma-617 has been its short half-life and fast rate of clearance. the investigators designed and synthesized a new radiopharmaceutical based on psma-11, p16-093. 68ga-p16-093 showed higher tumor uptake and clear blood clearance than 68ga-psma-617. then, the investigators shynthesis a new therapeutic radiopharmaceutical based on p16-093, p17-087; and the investigators added a selected albumin binder into p17-088 to synthesis another new radiopharmaceutical, p17-088. this study was designed to investigate the safety, dosimetry and preliminary effects of 177lu-p17-087/177lu-p17-088 in patients with metastatic castration-resistant prostate cancer.

Eligibility criteria:
inclusion criteria: * all the patients had progressive metastatic castration-resistant prostate cancer that did not respond to androgen-suppression therapy and/or systemic chemotherapy; * distant metastases with high psma expression were confirmed on 68ga-psma pet/ct within one week before the injection of 177lu-p17-087/177lu-p17-088. exclusion criteria: * patients were excluded if they had \[18f\]fdg positive tumors without corresponding psma uptake. patients were also not eligible if they accepted other radionuclide therapies within 6 months or had clinically significant impaired bone marrow, liver, or kidney function with a hemoglobin level of less than 9.0 g/dl, a white blood cell count of less than 2.5×109/l, a platelet count of less than 100×109/l and a serum creatinine \> 100 μmol/l.
scoring system for thyroid gland pathologies

Conditions: Thyroid Nodule; Thyroid Cancer

Summary: although anamnesis and physical examination remain the place in the evaluation of patients today; laboratory values, imaging methods and pathology results have come to the fore in the decision-making of surgery for patients. as a result of all other criteria, a follow-up decision can be changed in a patient with a single fine needle aspiration biopsy result, or despite all the examinations the investigators have, a clear result cannot be achieved, and patient management may be disrupted. a holistic approach to thyroid gland pathologies is planned thanks to the scoring system that will be created in this study.

in routine clinical practice, the criteria the investigators consider during the pre - op period in patients evaluated due to thyroid pathologies include anamnesis, physical examination, laboratory values, especially thyroid function, thyroid-neck ultrasonographies, fine needle aspiration biopsies, according to which decisions about operation or nonoperative follow-up are made with the patient. the investigators aim to create a common scoring system by taking into account the pathology results of patients who have undergone thyroidectomy and comparing these results with the results of pre-op examination and thus to address patient management in a more objective and comprehensive way.

Eligibility criteria:
inclusion criteria: * patients who undergone surgery for thyroid gland pathologies exclusion criteria: * patients who did not want to be involved in the study * patients who missed in the follow-up period * pregnant patients

Keywords: ti-rads bethesda
halliwick and aquatic exercises in spastic cerebral palsy

Conditions: Spastic Cerebral Palsy

Summary: the aim of this research is to find and compare the effects of halliwick exercises and aquatic exercises on gross motor function, trunk stability and hand function in spastic cerebral palsy.

randomized controlled trials done at dream child institute and children hospital complex multan. the sample size was 32. the subjects were divided in two groups, 16 subjects in halliwick exercise group and 20 in aquatic exercise group. study duration was of 6 months. sampling technique applied was convenient non probability sampling technique. only 13-16 years diagnosed spastic cerebral pals individuals were included. tools used in the study are gross motor function measure (gmfm-66), trunk impairment scale (tis) and nine-hole peg test (nhpt). data was being analyzed through spss 22.

Eligibility criteria:
inclusion criteria: * both genders male \& female * age 13-16 years * able to use assistive devices * diagnosed cp children * able to follow verbal commands exclusion criteria: * unstable seizures * had a surgery for the last 12 months or receive medication for spasticity * associated cognitive issue * incontinence * persistent infection

Keywords: halliwick exercises aquatic exercises gross motor function measurment trunk control
evisualisation of physical activity and pain (evis) for patients with chronic pain

Conditions: Chronic Pain

Summary: introduction: living with chronic pain often involves negative consequences. interdisciplinary pain rehabilitation programs (iprps), a subset of interdisciplinary treatment (idt) includes physical activity and exercise and is considered superior to single-treatment measures in patients with chronic pain. however, effects emerge sub-optimal and as many as 30% of patients deteriorate in some outcomes. a novel intervention, evisualisation (evis) of physical activity and pain, has been systematically developed to facilitate patients in reaching and maintaining recommended individualized physical activity levels. the aim is to transparently report on methodology, outcome assessments, and processes for a registry-based randomized controlled trial (r-rct) initiated as an internal pilot study. methods and analysis: the r-rct will recruit approximately 400 patients with chronic pain who are registered at primary and specialized iprp units (n=15) in sweden. participants will be randomly allocated to either an iprp + evis or the control group that will receive only iprp treatment. evis entails objectively measured physical activity (steps) and patient-reported outcomes (pain intensity, affect on daily activities, pharmaceutical consumption) collected and visualized in the web application patron. data from an initial 30 participants completing the study period (6 months) will be included in a pilot study designed to evaluate recruitment- and randomization processes, standardized effect size, sample size, characteristics of outcomes, follow-up rates of the r-rct. outcome variables will be extracted from patron and from six national registries. multivariate statistics and repeated measures analyses will be performed. quality adjusted life years (qalys) and incremental cost effectiveness ratio (icer) will be calculated for cost effectiveness evaluation. ethics/dissemination: the swedish ethics review board granted approval (dnr 2021/02109). results will be disseminated through peer-review journals.


Eligibility criteria:
inclusion criteria: swedish iprp treatment criterias will be applied as patients entering the trial must be accepted for iprp: principal iprp inclusion criteria are: * persistent or intermittent pain lasting ≥3 months * pain affecting daily activities to a large extent, * completed systematic assessment and non-pharmacological optimization is completed, * screening for psychosocial risk factors and differential diagnosis completed in addition the following criterias will be appled: * patients aged 18-67 years. * patients must be able to hear, see, and comprehend spoken and written swedish * daily access to a computer, smartphone, or tablet. exclusion criteria: * patients who need to use a walking aid indoors. * patients living with pain caused by systemic disease or malignancies.

Keywords: chronic pain registry-based randomized clinical trial
outpatient care pathway for patients treated intra-arterially for primary liver cancer

Conditions: Hepato Cellular Carcinoma (HCC)

Summary: randomized trial comparing two care organizations (outpatient versus conventional inpatient care) using a mixed method (quantitative and qualitative data and analysis). the protocol involves randomization between an ambulatory group and a conventional hospitalization group. patients will be monitored for 7 months to assess satisfaction, complications and treatment efficacy. a qualitative study will be carried out to understand the obstacles and facilitate implementation of the ambulatory pathway. a medico-economic analysis will accompany this study to assess the financial impact of adopting the ambulatory pathway. the expected results will help determine the best management strategy for these patients. the study's hypotheses are that performing intra-arterial treatments for primary liver cancer on an outpatient basis, combined with telephone follow-up, will improve patient satisfaction with their care, and that analysis of the implementation of this outpatient pathway will help improve the pathway and facilitate its implementation at other sites, by identifying obstacles and solutions.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * hcc or cci diagnosed according to the criteria of the european association for the study of the liver (2024) or histologically proven. * hcc or cci naive to intra-arterial treatment. hcc may have been previously treated with other non-intra-arterial therapies. other hcc may have been previously treated but not with intra-arterial therapy. * if hcc treatment is proposed at a multidisciplinary consultation meeting (rcp): * patient child-pugh \< b8 * single or multiple hcc * absence of lobar or truncal portal obstruction * absence of bile duct dilatation * if treatment by reh proposed in rcp: * absence of truncal portal tumor invasion * uni-lobar tumor invasion (except for centrohepatic cci) * total bilirubin \< 20 mg/l (or 35 µmol/l) * patient affiliated to or benefiting from a social security scheme * patient having signed an informed consent form exclusion criteria: * technical contraindication or morphological elements of predictable technical difficulty * chronic renal insufficiency (clairance \< 30 ml/min) * known allergy to a contrast agent or chemotherapy agent * patient unable to be a candidate for outpatient management * patient previously included in the study * patient who, for psychological, social, family or geographical reasons, could not be regularly monitored, patient who, for psychological, social, family or geographical reasons, could not be followed regularly * concomitant disease or severe uncontrolled clinical situation * severe uncontrolled infection * pregnant, breast-feeding or parturient woman * person deprived of liberty by judicial or administrative decision * person under compulsory psychiatric care * person under a legal protection measure * person unable to give consent

Keywords: ambulatory care hospitalization hepato cellular carcinoma patient satisfaction randomized trial chemoembolization radioembolization
innovation in mammography: tomosynthesis pathways

Conditions: Breast Cancer

Summary: the study aims at evaluating the introduction of tomosynthesis in mammography screening, analyzing the benefits, disadvantages and feasibility in current clinical practice. it involves women aged 45-46 that will be divided, by drawing lots, into two groups: one group will do the 2d digital mammography (control group), while the other group (intervention group) will do tomosynthesis. in the intervention group the 2d two-dimensional mammography will be reconstructed starting from tomosynthesis without exposing women to other radiation.

the impeto trial is a population-based, multicentre, randomised trial aimed at evaluating the clinical accuracy of digital breast tomosynthesis (dbt) in adjunct to synthetic mammograms (sdm) compared to standard two-dimensional digital mammography alone (2d) in a screening programme. 45-46 year-old women resident in the screening centre catchment area of florence and south-est local health unit are invited to attend for mammography screening and asked for informed consent to be included in the study. women are then randomly allocated either to an usual care group (2d mammography) or to the intervention group. in the intervention group, dbt combined with sdm is proposed in order to reduce radiation exposure. the next year women of both groups will be invited to attend the usual screening examination (2d mammography). the enrolment will last 12-18 months; the whole study 36 months. the estimated sample size is 6000 women, 3000 per arm. data will be pooled with the trial "screening for breast cancer with digital breast tomosynthesis", clinicaltrials.gov identifier: nct02698202.

Eligibility criteria:
inclusion criteria: * 45-46 years old women resident in the screening area exclusion criteria: * previous breast cancer * written refusal to participate in the screening programme * pregnancy, breastfeeding * presence of prostheses; * ongoing chemotherapy; * impossibility to submit the informed consent for linguistic problems or for inability of women to provide informed consent; * verified presence of brca1 - brca2 (breast related cancer antigens 1 - breast related cancer antigens 2) genetic mutation or involvement in surveillance path for heredo-familial tumor; * previous known tomosynthesis.

Keywords: breast cancer screening tomosynthesis digital mammography
behavioral therapy for children and adolescents with tourette syndrome

Conditions: Tourette Syndrome

Summary: tourette syndrome (ts) is a common neuropsychiatric disorder in childhood and adolescence, and often comorbid with psychiatric comorbidity. antipsychotic medications are usually the first choices, but may associate with adverse effects. behavioral intervention for ts has been shown to be an effective treatment for children and adolescents, yet have not been performed and evaluated using control trails in taiwan.

ts is a common neuropsychiatric disorder in childhood and adolescence, and often comorbid with psychiatric comorbidity. antipsychotic medications are usually the first choices, but may associate with adverse effects. behavioral intervention for ts has been shown to be an effective treatment for children and adolescents, yet have not been performed and evaluated using control trails in taiwan. this study therefore was to evaluate the efficacy of a comprehensive behavioral intervention therapy on improving tics and tic-related impairment for children and adolescents with tourette syndrome.

Eligibility criteria:
inclusion criteria: * dsm-5 diagnostic criteria for tourette syndrome * patients aged from 6-15 years who were diagnosed with ts or ctd, * never received any pharmacological treatment * ability to understand the study purpose and/or provide consent for participation independently and via a caregiver serving as a proxy exclusion criteria: * have been diagnosed with another mental illness, * had no physical or medical condition, * had been received cbit or cognitive behavior therapy before.

Keywords: tourette syndrome behavior therapy children and adolescents
effects of pg2 on fatigue-related symptom clusters

Conditions: Cancer-related Fatigue

Summary: this study is for an "add-on" study to the "main" study (protocol no.: ph-cp012). the information of patients from main study will be collected by questionnaire survey and actigraphy measurement to evaluate the relationship between fatigue, depression and sleep disorder and the efficacy of pg2 after treatment.the association between symptom cluster and circadian rhythm will be also further explored.

the study is "pg2 treatment for improving fatigue among advanced cancer patients under standard palliative care" (protocol number: ph-cp012) of the additional plan, through questionnaires and using actigraphy measuring circadian rhythm collect patient data master plans, assessed for "pg2" treatment of cancer patients before and after treatment fatigue, depression, sleep disorders and other related symptoms of resistance and the effectiveness of treatment, and to further explore the symptom clusters in cancer patients associated with the circadian rhythm

Eligibility criteria:
inclusion criteria: * patients who signed the informed consent form * the age of eligible patients should be 20 years old. * eligible patients must have locally advanced or metastatic cancer or inoperable advanced cancer. * patients are under standard palliative care (spc) at hospice setting and have no further curative options available. * patients with bfi fatigue score 4 during screening. * patients have a life expectancy of at least 3 months as determined by the investigator. * patient must be willing and able to complete quality of life questionnaires. exclusion criteria: * female patients are pregnant or breast-feeding. * patients with uncontrolled systemic disease such as active infection, severe heart disease, uncontrollable hypertension or diabetes mellitus. * patients take central nervous system stimulators such as methylphenidate within 30 days before screening. * patients have enrolled or have not yet completed other investigational drug trials within 30 days before screening. * patients with karnofsky performance scores less than 30 % at time of screening * patients who are diagnosed as dying status
sox as salvage treatment in nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma

Summary: the aim of the study is to evaluate the efficacy and safety of sox regimen (s-1 plus oxaliplatin) as salvage treatment in patients with relapsed or metastatic nasopharyngeal carcinoma.

the treatment option in patients with platinum-resistant relapsed or metastatic nasopharyngeal carcinoma is limited. previous studies showed that both s-1 and oxaliplatin were effective in head and neck cancer. moreover, sox (s-1 plus oxaliplatin) was proved to be tolerable in advanced stage gastric cancer. therefore, we aim to evaluate this regimen in salvage setting of nasopharyngeal carcinoma.

Eligibility criteria:
inclusion criteria: * age range: 18-75 years old * histological confirmed incurable relapsed or metastatic nasopharyngeal carcinoma * prior exposure of at least one line of platinum-containing regimen * ecog performance status 0-1 * life expectancy of more than 3 months * bone marrow function: anc≧1.5×109/l, plt≧100×109/l, hb≧80g/l * liver function: total bilirubin, alt and ast \<1.5×unl * renal function: cr\<1.5×unl, ccr≧50ml/min * without \> 1 grade of neuropathy exclusion criteria: * with curable treatment option * with cns involvement * prior platinum exposure only in neo-adjuvant/adjuvant setting or concurrently used with radiotherapy * treated with \> 2 lines of palliative chemotherapy * with prior exposure of s-1 or oxaliplatin * history of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix * significant active infection * pregnant or lactating women

Keywords: nasopharyngeal carcinoma s-1 oxaliplatin
clinical efficacy of virtual reality during office hysteroscopy and endometrial biopsy in subfertility

Conditions: Infertility, Female

Summary: this study is a comparison between the current standard practice of performing a diagnostic hysteroscopy and a relatively recently developed technology that is added to the standard diagnostic hysteroscopy. the aim of the study is to find out whether this newer technology has an advantage for the patient, in the form of anxiety and pain reduction.


Eligibility criteria:
inclusion criteria: * undergoing fertility treatments * for which outpatient hysteroscopy has been prescribed * for different possible indications: suspicion of intracavitary pathology, recurrent implantation failure, recurrent early pregnancy loss, ... exclusion criteria: 1. hearing impairments and blindness 2. motion sickness 3. any known anatomical characteristics that may make performing the office procedure impossible. 4. the unwillingness of the patient to undergo an office hysteroscopy 5. denial or withdrawal of informed consent

Keywords: virtual reality hysteroscopy infertility